← All stocks

TEVA PHARMACEUTICAL INDUSTRIES LTD

TEVA No buying or selling
CIK 0000818686 #599 in the set updated 21 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
$0.00
$0.00 against sales at will

By person

23 insiders · 0 transactions
25.8×

Richard Francis holds 25.8 times base salary in stock. $43.86M of shares against $1.70M in salary for 2025.

Salary from the company's own proxy. The shares are what Richard Francis last reported holding, valued at $37.25, the price Ordinary Shares was last bought or sold at on the open market here, on 21 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Elstein Amir
Director
2,118,455
$78.91M
+1.2%
Francis Richard D
President and CEO
1,177,529
$43.86M
+855.1%
MIGNONE ROBERTO
Director
487,407
$18.16M
−54.7%
BARER SOL J
Director
448,011
$16.69M
+9.5%
Hughes Eric A
See "Remarks"
134,877
$5.02M
LIEBERMAN GERALD M
Director
130,149
$4.85M
+22.8%
Crane Rosemary A
Director
127,739
$4.76M
+23.3%
Nisen Perry
Director
119,807
$4.46M
+25.2%
Satchi-Fainaro Ronit
Director
111,986
$4.17M
+26.9%
Sabag Mark
See "Remarks"
80,760
$3.01M
−78.9%
Vergis Janet S.
Director
73,697
$2.75M
+15.0%
Zaks Tal Zvi
Director
73,247
$2.73M
+49.1%
Kalif Eliyahu Sharon
EVP, Chief Financial Officer
65,621
$2.44M
−67.8%
Fox Christine
EVP, U.S. Commercial
63,647
$2.37M
Daniell Richard
EVP, Europe Commercial
55,755
$2.08M
Lippman Evan
EVP, Business Development
25,591
$953.26K
Shalev Varda
Director
22,504
$838.27K
+74.8%
Lichtenstein Chen
Director
19,296
$718.78K
Weiss Amir
Chief Accounting Officer
13,071
$486.89K
+152.4%
McAvoy David R.
EVP, Chief Legal Officer
13,027
$485.26K
Savage Brian
Interim Chief Legal Officer
10,914
$406.55K
+1,377%
Jover Placid
See "Remarks"
6,774
$252.33K
Shields Matthew
EVP, Global Operations
0
$0.00

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 2
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 0
History held since 23 Jan 2018